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Most tumor markers have low detection rates for curable stages of cancer and are therefore not satisfactory for use
in a healthy population. A new cancer risk calculation method, AminoIndex Cancer Screening (AICS), uses multiple
plasma amino acid concentrations to calculate the risks for several cancers simultaneously and is suggested to have
a high detection rate for early-stage cancers and a low false-positive rate for adenomas. Here, we describe a male
patient with a family history of colorectal cancer who underwent AICS. He was judged as Rank C for colorectal
cancer, which reportedly has a specificity of 95%, a sensitivity of 41%, and an estimated positive predictive value of
0.67%. He underwent colonoscopy for a secondary screening, which revealed a 10-mm adenoma-like lesion in the
ascending colon, with a biopsy report of partial carcinoma. The tumor was endoscopically removed and diagnosed
as carcinoma in situ (carcinoma in adenoma). This early detection method allowed complete resection of the
carcinoma, and the patient is in remission. This is the first case in which a curable cancer was detected using AICS.
With its high detection rate for early-stage cancers and its ease of use, this tool, which recently became available in
Japan, may be beneficial for simultaneous screening of the general population for multiple cancers.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/2145080259887842
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Colorectal cancer is the third most common cancer in
the world, and the incidence rate of colorectal cancer is
increasing in Japan as diets become more westernized
[1]. As with most cancers, colorectal cancer survival is
highly dependent on the stage of disease at diagnosis.
Typical 5-year survival rates for colorectal cancer are
90% for cancers detected at the localized stage, 70% for
the regional stage, and 10% for people diagnosed with
distant metastatic cancer [2]. Early detection is suggested
to be beneficial; however, currently available methods
such as fecal occult blood testing and colonoscopy are
problematic owing to the low specificity and invasiveness,
respectively. In addition, detection rates of these methods* Correspondence: jyatabe@fmu.ac.jp
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reproduction in any medium, provided the orand tumor markers for early-stage cancers are not high
enough. As such, an effective method for screening has
not been established at present.
Here, we report a case of an early-stage colon cancer
detected using AminoIndex Cancer Screening (AICS).
AICS analysis compresses multidimensional information
from the plasma free amino acid profile into a single
score to maximize the differences between patients with
cancer and the control population [3].
Of many different metabolites in plasma, amino acids
are emerging as markers for various pathological con-
ditions because they are at the metabolic hub, being
synthesized and degraded in many key processes [4].
Reportedly, plasma amino acid profiling was useful in
diabetes risk assessment [5] and the diagnosis of liver fi-
brosis [6]. Meanwhile, cross-sectional studies have docu-
mented the potential of plasma amino acid profiling for
screening of lung [7], gastric [3], breast [8], colorectal [8],
and prostate [3] cancers. AICS takes advantage of theLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Plasma levels of 6 amino acids used in the colorectal
cancer risk calculation. Averages and percentile ranges of the
normal population are indicated because some amino acids do not
show normal distribution. The data of this patient are shown as
open circles. High plasma level of isoleucine is a prominent
characteristic of patients with colorectal cancer.
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raphy–electrospray mass spectrometry (HPLC–ESI–MS)
methods that enable high-throughput analysis of plasma
amino acids and both univariate and multivariate statis-
tical analyses. To build AICS, the following 19 amino acids
and related molecules are measured and statistically ana-
lyzed: alanine, arginine, asparagine, citrulline, glutamine,
glycine, histidine, isoleucine, leucine, lysine, methionine,
ornithine, phenylalanine, proline, serine, threonine, trypto-
phan, tyrosine, and valine. For the colorectal cancer AICS
score, plasma concentrations of serine, proline, valine, me-
thionine, isoleucine, and lysine are incorporated into the
formula. The minimum and maximum AICS values are
0.0 and 10.0, respectively, and AICS values of 5.0 and 8.0
correspond to specificities of 80% and 95%, respectively,
for each cancer [9]. There are 3 categories of AICS values:
rank A, <5.0; rank B, 5.0–8.0; and rank C, ≥8.0. Subjects
in the rank C category are said to have an approximately
10-fold cancer risk. Recently, Ajinomoto Co., Inc. began
to commercially provide AICS in Japan for 7 types of can-
cers: lung, gastric, colorectal, breast, prostate, mammary,
and uterine.
A characteristic of AICS is its relatively high sensitivity
for early-stage cancers. For AICS Rank C colorectal can-
cer, sensitivities were 55% for detecting Stage 0 cancer
(carcinoma in situ), 30% for Stage I cancer, 43% for Stage
II cancer, 42% for Stage III cancer, and 62% for Stage IV
cancer [9]. Therefore, AICS may be a good method in a
healthy population, particularly because it can be easily
performed and can simultaneously screen for various
cancers.
Case presentation
We report the first case of colon cancer detected using
this new technology. In September 2011, a 62-year-old
Japanese man whose mother died of colorectal cancer a
few years before requested cancer screening. He heard
about AICS, which had recently become available in
Japan, and requested it because it can be performed
along with routine blood testing and can simultaneously
screen for multiple types of cancers.
The patient had a history of urolithiasis, intervertebral
disc displacement, impaired glucose tolerance, and hyper-
tension, for which he was receiving amlodipine at 5 mg/
day. He had no history of cancer, and his annual colorectal
cancer screening using fecal occult blood was negative in
2010. For his chronic lumbago and a vertebral lesion ob-
served on magnetic resonance imaging, an orthopedic
doctor recommended positron emission tomography–
computed tomography (PET–CT) using 18 F-fluorodeox-
yglucose in September 2011. No abnormal accumulation
was observed on PET–CT (data not shown).
For AICS, 5 mL of blood was collected after over-
night fasting from forearm veins in tubes containingethylenediaminetetraacetic acid and kept at approximately
0°C until plasma preparation [10]. The plasma was stored
at −80°C until analysis. Plasma amino acid concentrations
were measured by HPLC–ESI–MS (SRL, Inc., Tokyo,
Japan) after deproteinization [11]. Ajinomoto Co., Inc.
(Tokyo, Japan) commercially performed the AICS calcu-
lation using plasma amino acid concentrations. The pa-
tient’s AICS score for colorectal cancer was 8.3, which
belonged to Rank C. Figure 1 shows the plasma levels of 6
amino acids used in the colorectal cancer risk calculation.
High plasma level of isoleucine is a prominent characteris-
tic of patients with colorectal cancer [3,8], which was also
observed in the index patient. The patient did not have
liver dysfunction, chronic kidney disease, or diabetes mel-
litus that may affect the results of AICS. His fasting blood
glucose level was 113 mg/dL (6.28 mmol/L, normal range:
70–109 mg/dL) and glycated hemoglobin (HbA1C) level
was 5.6% (normal range: 4.6%–6.2%). His conventional
tumor markers were within the normal range: carcinoem-
bryonic antigen (CEA) was 1.2 ng/mL (normal range:
below 5.0 ng/mL) and carbohydrate antigen (CA) 19–9
was 3.6 U/mL (normal range: below 37.0 U/mL). The pa-
tient’s AICS scores for other types of cancer were also nor-
mal (gastric 0.0, lung 0.8, and prostate 0.3).
AICS Rank C for colorectal cancer suggests the need
for further workup such as colonoscopy. His colonos-
copy in October 2011 revealed an adenoma-like lesion
of 10-mm diameter in the ascending colon (Figure 2A,
B). Carcinoma in adenoma was observed in the biopsy
sample (Figure 2E). To remove the lesion, endoscopic
mucosal resection (Figure 2C, D) was performed by a
physician certified by the Japan Gastroenterological En-
doscopy Society. The dissected specimen also revealed a
carcinoma in situ (Figure 2F), which was the final diag-





Figure 2 Endoscopic and microscopic observations of the
lesion. A: the tumor observed in the ascending colon by colonoscopy,
B: a close-up narrow-band imaging of the tumor, C: endoscopic
submucosal dissection of the tumor, D: the site immediately after tumor
removal, E: the biopsy specimen with hematoxylin–eosin staining,
F: sections of the removed tumor with hematoxylin–eosin staining, G:
the dissection scar, 6 months later, with indigo carmine dye, and H: a
close-up view of the dissection scar.
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men, and follow-up colonoscopy after 6 months showed
normal scarring, free of local recurrence (Figure 2G, H).
Discussion
The index patient was the first case in which curable
cancer was detected using AICS. In the case presented,
only AICS showed the possibility of colorectal cancer at
the initial screening. Fecal occult blood testing and
PET–CT performed in the same year as AICS werenegative. Fecal occult blood testing is commonly per-
formed in Japan to screen for colorectal cancers. Specifi-
city and sensitivity of fecal occult blood testing are
reportedly 91.4% and 67%, respectively, for clinically sig-
nificant colorectal tumors, including cancers and ad-
vanced polyps. However, its sensitivity decreases for
tumors in the ascending colon, being 11.2% for cancers
and adenomas of 10 mm or larger. Furthermore, these
studies are limited because they analyze cancers and
large adenomas together. In contrast, Rank C in AICS
has a specificity of 95%, better than that reported for
fecal occult blood testing, and a sensitivity of 41% for
colorectal cancer. AICS also has a high detection rate for
early-stage cancers, with a sensitivity of 55% for Stage 0
intramucosal carcinoma, and the sensitivity of AICS re-
portedly has no significant relationship with tumor staging
[9]. This is in contrast to most tumor markers that have
low detection rates for curable stages of cancer and are
therefore not satisfactory for use in a healthy population.
In addition to its potential in detecting early disease,
AICS may be more effective than fecal occult blood test-
ing or colonoscopy for detecting cancers of the proximal
colon such as the one in the index patient because
plasma is used for AICS analysis. Moreover, AICS may
differentiate a carcinoma from adenoma relatively well
as AICS Rank C has a positive rate of 41% for colorectal
cancer but only 7% for colorectal polyp. Therefore, AICS
may also aid in the decision of whether biopsy should be
performed in addition to general screening for an
adenoma-like lesion found on colonoscopy.
It needs to be noted that AICS has only been tested
for colorectal adenocarcinoma and not for other, rarer
tumorous lesions in the intestines such as phyllodes
tumor [12], malignant melanoma [13], and intestinal
endometriosis [14]. The probable cell-type specificity is
similar to other potential molecular diagnostics and
prognostics methods such as special AT-rich sequence-
binding protein 1 (STAB1) expression [15], beta-catenin
alterations and microsatellite instability (MSI) [16] in
colorectal cancer.
Also, it needs to be kept in mind that the studies on
AICS have been performed only on Japanese subjects
till date. Whether the same diagnostic algorithm ap-
plies to other races remains to be tested. In addition,
the causality and mechanisms of plasma amino acid al-
terations have not been determined and are targets of
further study.
Conclusion
In summary, an early-stage colon carcinoma was found
following the positive result by AICS calculated from
plasma amino acid concentrations. This early detection
enabled complete resection of the carcinoma. AICS could
be a good method to screen the general population because
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false-positive rate for adenomas, and it can assess the
risks of multiple cancers simultaneously with single
blood collection.
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